OBJECTIVES

Assessment the financial burden on Moscow health care when using vedolizumab compared to TNF-α inhibitors for treating adult patients with moderate or severe active ulcerative colitis and moderate or severe active Crohn’s disease with an unsatisfactory response, loss of response or intolerance to prior therapy.

METHODS

166 adult patients with the established diagnosis moderate to severe UC and 289 adult patients with the established diagnosis of CD moderate to severe form. 58 patients with CD and 33 patients with UC underwent a permanent change of biologicals, which allowed us to make an assumption about the ineffectiveness / lack of effectiveness of the therapy, and as a result about the excessive burden on the budget. Biologicals drug supply for these cohorts of patients were included analysed.

RESULTS

The results of the comparison showed that including vedolizumab will achieve economic benefits for the budget of Moscow for UC will allow to achieve an economic advantage for the budget of Moscow in the form of 1 616 966.07 rubles, and for CD - an economic advantage -141 555.67 rubles. Transferring the additional number of UC and CD patients from other biologicals to vedolizumab allows achieving even greater economic efficiency.

CONCLUSIONS: Evidenced-based possibilities of changing drug supply with biologicals of patients UC and CD in Moscow. The clinical and economic efficacy of the advantages of the primary purpose of vedolizumab compared with the conversion of patients to other TNF-α inhibitors was demonstrated. A vector for further prospective development has been determined with the aim of improving the quality of medical care for Moscow residents and increasing the availability of biologicals drug supply for patients with UC and CD.